Results 81 to 90 of about 59,669 (311)
British Journal of Clinical Pharmacology, EarlyView.Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet +6 more
wiley +1 more source
Vitamin D—A prominent immunomodulator to prevent COVID‐19 infection
International Journal of Rheumatic Diseases, Volume 26, Issue 1, Page 13-30, January 2023., 2023 Abstract COVID‐19 remains a life‐threatening infectious disease worldwide. Several bio‐active agents have been tested and evaluated in an effort to contain this disease. Unfortunately, none of the therapies have been successful, owing to their safety concerns and the presence of various adverse effects.
Sumel Ashique +13 more
wiley +1 more source
In Silico Investigations on the Potential Inhibitors for COVID-19 Protease [PDF]
arXiv, 2020 A novel strain of coronavirus, namely, COVID-19 has been identified in Wuhan city of China in December 2019. There are no specific therapies available and investigations regarding the treatment of the COVID-19 are still lacking. This prompted us to perform a preliminary in silico study on the COVID-19 protease with anti-malarial compounds in the search
arxiv
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
Качественная клиническая практика, 2020 Taking recent publications into account, one should consider avoiding routine use of hydroxychloroquine, especially if combined with azithromycin, for COVID-19.
V. A. Otdelenov +4 more
doaj +1 more source
Searching inhibitors for three important proteins of COVID-19 through molecular docking studies [PDF]
arXiv, 2020 The lack of recommended drugs or vaccines to deal with the COVID-19 is the main concern of this pandemic. The approved drugs for similar health problems, drugs under clinical trials, and molecules from medicinal plants extracts are investigated randomly to deal with the COVID-19 infection.
arxiv
Hydroxychloroquine shortage [PDF]
British Dental Journal, 2020 Patel, J., Coulthard, P.
openaire +2 more sources
Toxicology Reports, 2019 Hydroxychloroquine is a medication used to treat autoimmune conditions. Overdoses of hydroxychloroquine are uncommon, with most recommendations on monitoring drawing from experience with more common overdoses of the related drug chloroquine. We present a
Joshua B. Radke +3 more
doaj
Data on hydroxychloroquine interference with urine laboratory testing
Data in Brief, 2019 Hydroxychloroquine is a medication used to treat rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune disorders. Previous studies have shown that hydroxychloroquine and the structurally related drug chloroquine have the potential to ...
Jennie M. Kingery +3 more
doaj
Chinese Medicine, 2020 Purpose To investigate the effect of total glucoside of paeony (TGP) on gut microbiota in NOD mice with Sjögren’s syndrome (SS), using high-throughput sequencing of 16SrRNA gene.
Wen-Wen Lu +5 more
doaj +1 more source
Nature Communications, 2021 Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine
Cathrine Axfors +93 more
doaj +1 more source